Exploratory analyses identified neutralizing antibody responses elicited by the H2HA-Ferritin vaccine in both H2-naive and H2-exposed populations. Both vaccines were safe and well tolerated, with the most common solicited symptom being mild headache after both H2HA-Ferritin ( n = 15, 22%) and H2 DNA ( n = 5, 25%). The secondary objective was to evaluate antibody responses after vaccination.

The primary objective of this trial was to evaluate the safety and tolerability of H2HA-Ferritin either alone or in prime-boost regimens. Fifty healthy participants 18–70 years of age received H2HA-Ferritin intramuscularly as a single 20-μg dose ( n = 5) or a 60-μg dose either twice in a homologous ( n = 25) prime-boost regimen or once in a heterologous ( n = 20) prime-boost regimen after a matched H2 DNA vaccine prime. Including both H2-naive and H2-exposed adults in the trial allowed us to evaluate memory responses against the conserved stem domain in the presence or absence of pre-existing responses against the immunodominant HA head domain. Adults born after 1968 have been exposed to only the H1 subtype of group 1 influenza viruses, which shares a conserved stem with H2.

The H2 subtype has not circulated in humans since 1968. We conducted a first-in-human, randomized, open-label, phase 1 clinical trial ( NCT03186781) to evaluate a novel ferritin (H2HA-Ferritin) nanoparticle influenza vaccine platform. Nature Medicine volume 28, pages 383–391 ( 2022) Cite this articleĬurrently, licensed seasonal influenza vaccines display variable vaccine effectiveness, and there remains a need for novel vaccine platforms capable of inducing broader responses against viral protein domains conserved among influenza subtypes. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Cold Iron by D.L. McDermott